INHIBRX BIOSCIENCES, INC. Net Income
INHIBRX BIOSCIENCES, INC. (INBX) reported Net Income of -$36.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$36.65M.
- INHIBRX BIOSCIENCES, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$33.44M.
- INHIBRX BIOSCIENCES, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$32.83M.
- INHIBRX BIOSCIENCES, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$35.26M.
- INHIBRX BIOSCIENCES, INC. net income (loss) attributable to parent for fiscal 2025 was -$140.06M, a 108.30% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. net income (loss) attributable to parent for fiscal 2024 was $1.69B.
- INHIBRX BIOSCIENCES, INC. net income (loss) attributable to parent for fiscal 2023 was -$241.36M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$36.65M 10-Q · filed 2026-08-13 | -$70.09M 10-Q · filed 2026-08-13 | -$102.92M derived: sum of 3 quarters · filed 2026-08-13 | -$138.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$33.44M 10-Q · filed 2026-08-13 | -$66.28M derived: sum of 2 quarters · filed 2026-08-13 | -$101.53M derived: sum of 3 quarters · filed 2026-08-13 | -$130.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$32.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$68.09M derived: sum of 2 quarters · filed 2026-03-19 | -$96.74M derived: sum of 3 quarters · filed 2026-08-13 | -$140.06M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$35.26M 10-Q · filed 2025-11-14 | -$63.91M derived: sum of 2 quarters · filed 2026-08-13 | -$107.22M 10-Q · filed 2025-11-14 | -$155.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$28.65M 10-Q · filed 2026-08-13 | -$71.97M 10-Q · filed 2026-08-13 | -$119.83M derived: sum of 3 quarters · filed 2026-08-13 | -$163.69M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$43.31M 10-Q · filed 2026-08-13 | -$91.18M derived: sum of 2 quarters · filed 2026-08-13 | -$135.04M derived: sum of 3 quarters · filed 2026-08-13 | $1.72B derived: sum of 4 quarters · filed 2026-08-13 |
| 2024-12-31 | -$47.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$91.73M derived: sum of 2 quarters · filed 2026-03-19 | $1.77B derived: sum of 3 quarters · filed 2026-03-19 | $1.69B 10-K · filed 2026-03-19 |
| 2024-09-30 | -$43.86M 10-Q · filed 2025-11-14 | $1.81B derived: sum of 2 quarters · filed 2025-11-14 | $1.74B 10-Q · filed 2025-11-14 | $1.64B derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.86B 10-Q · filed 2025-11-14 | $1.78B 10-Q · filed 2025-08-13 | $1.69B derived: sum of 3 quarters · filed 2025-11-14 | $1.63B derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-03-31 | -$78.71M 10-Q · filed 2025-11-14 | -$172.31M derived: sum of 2 quarters · filed 2025-11-14 | -$224.10M derived: sum of 3 quarters · filed 2025-11-14 | -$271.15M derived: sum of 4 quarters · filed 2025-11-14 |
| 2023-12-31 | -$93.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$145.39M derived: sum of 2 quarters · filed 2025-03-17 | -$192.44M derived: sum of 3 quarters · filed 2025-03-17 | -$241.36M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$51.79M 10-Q · filed 2024-11-14 | -$98.84M derived: sum of 2 quarters · filed 2024-11-14 | -$147.76M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$47.05M 10-Q · filed 2024-11-14 | -$95.97M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$48.92M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |